注射用丹参多酚酸盐联合培美曲塞及卡铂治疗老年人晚期非鳞非小细胞肺癌效果观察

目的 观察注射用丹参多酚酸盐联合培美曲塞及卡铂方案治疗老年人晚期非鳞非小细胞肺癌的效果和安全性。方法 经组织病理学或细胞学证实初治老年晚期非鳞非小细胞肺癌患者58例，通过区组随机化法分为对照组和观察组各29例。对照组给予培美曲塞＋卡铂方案化疗，观察组在对照组治疗基础上给予注射用丹参多酚酸盐200 mg／次，1次／d，静脉滴注，连用14 d。21 d为１个周期，4个周期后比较两组近期疗效、生活质量、不良反应发生及凝血指标改善情况。结果 观察组和对照组总有效率分别为44.8 %（13／29）、37.9 %（11／29），疾病控制率分别为86.2 %（25／29）、75.8 %（22／29）， 两组近期疗效比较差异无统计学意义（P＞0.05），观察组生活质量总改善率优于对照组[82.7 %（24／29）比65.5 %（19／29）]（P＜0.05），血液学毒性和消化道反应发生率低于对照组（P＜0.05），且观察组血液高凝状态改善情况优于对照组（P＜0.05）。结论 注射用丹参多酚酸盐联合培美曲塞、卡铂方案治疗老年人晚期非鳞非小细胞肺癌可降低化疗引起的不良反应，提高患者生活质量，改善肺癌患者的血液高凝状态，从而预防血栓栓塞性并发症的发生。

The efficacy of salvianolate injection combined with pemetrexed and carboplatin in the treatment of elderly patients with advanced non-squamous non-small-cell lung cancer

Objective To observe the efficacy and safety of salvianolate injection combined with pemetrexed and carboplatin in the treatment of elderly patients with advanced non-squamous non-small-cell lung cancer. Methods 58 elderly patients with advanced non-squamous non-small-cell lung cancer in primary treatment were diagnosed by histopathology or cytology confirmation, and they were randomly divided into two groups （29 patients for control group and 29 patients for observation group）. The control group was subjected to pemetrexed plus carboplatin chemotherapy, while the observation group was subjected to salvianolate injection based on the treatment of the control group by intravenous drip for 14 days, once a day, 200 mg per day, and 21 days was a cycle. The changes of the efficacy, quality of life, the incidence of adverse reactions and the coagulation indicators in the patients of the two groups were compared after 4 cycles. Results The response rates and disease control rates in observation group were 44.8 % （13/29）, 86.2 % （25/29） and 37.9 % （11/29）, 75.8 % （22/29）. It was found that the comparison of efficacy between the two groups did not make any statistical differences （P 〉 0.05）. The improvement of the quality of life in the observation group [82.7 % （24/29）] was better than that of the control group [65.5 % （19/29）] （P 〈 0.05）. The hematologic toxicity and gastrointestinal reaction rate in the observation group was lower compared with the control group （P 〈 0.05）. Moreover, the improvement of the hypercoagulable states in the observation group was better than that of the control group （P 〈 0.05）. Conclusions The treatment on elderly patients with advanced non-squamous non-small-cell lung cancer by salvianolate injection combined with pemetrexed and carboplatin can reduce the adverse effects caused by chemotherapy, improve the quality of life and the hypercoagulable states. Thereby it might prevent the occurrence of thromboembolic complications.